Schocket Alan L
Division of Allergy and Clinical Immunology, University of Colorado School of Medicine, Denver, USA.
Allergy Asthma Proc. 2006 Mar-Apr;27(2):90-5.
Chronic urticaria (CU) is a relatively common but vexing disease. The pathophysiology is based on the cutaneous mast cell release of mediators, predominantly histamine. Release can be induced via specific immunoglobulin E (IgE), components of complement activation and nonspecifically by various compounds including endogenous peptides, endorphins, and enkephalins. In >30% of CU patients, autoimmune phenomena have been found, characterized by positive autologous serum skin test, antibodies to the alpha-subunit of the basophil IgE receptor, to IgE itself, and, perhaps, the most clinically relevant, thyroid autoimmunity. Studies suggest that the products of the activated immune system can lower the cutaneous mast cell release threshold, possibly allowing activation by endogenous compounds. The resulting release of mediators produces the clinical picture of recurrent hives. Although the goal of management of CU is the identification of a treatable cause, in most CU patients, especially adults, a cause is not frequently found. Identified causes include drugs, foods, infections, immune complex production leading to urticarial vasculitis, autoantibody production, and underlying autoimmune disease, particularly autoimmune thyroiditis. The treatment of the thyroiditis with suppressive doses of thyroid hormone often results in the remission of the CU. Given the marginally effective and sometimes dangerous medical therapy available for CU, a systematic and thorough approach to identify a treatable cause in difficult CU patients is warranted.
慢性荨麻疹(CU)是一种相对常见但令人困扰的疾病。其病理生理学基于皮肤肥大细胞释放介质,主要是组胺。释放可通过特异性免疫球蛋白E(IgE)、补体激活成分诱导,也可由包括内源性肽、内啡肽和脑啡肽在内的各种化合物非特异性诱导。在超过30%的CU患者中发现了自身免疫现象,其特征为自体血清皮肤试验阳性、针对嗜碱性粒细胞IgE受体α亚基的抗体、针对IgE本身的抗体,以及可能与临床最相关的甲状腺自身免疫。研究表明,激活的免疫系统产物可降低皮肤肥大细胞的释放阈值,可能使内源性化合物激活肥大细胞。由此产生的介质释放导致了反复发作的荨麻疹的临床表现。尽管CU的治疗目标是确定可治疗的病因,但在大多数CU患者中,尤其是成年人,病因并不常见。已确定的病因包括药物、食物、感染、导致荨麻疹性血管炎的免疫复合物产生、自身抗体产生以及潜在的自身免疫性疾病,特别是自身免疫性甲状腺炎。用抑制剂量的甲状腺激素治疗甲状腺炎通常会使CU缓解。鉴于现有的针对CU的药物治疗效果有限且有时存在危险,对于难治性CU患者,有必要采用系统而全面的方法来确定可治疗的病因。